Cargando…

Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy

Epacadostat (EPA), the most advanced IDO1 inhibitor, in combination with PD-1 checkpoint inhibitor, has failed in a recent Phase III clinical trial for treating metastatic melanoma. Here we report an EPA nanovesicle therapeutic platform (Epacasome) based on chemically attaching EPA to sphingomyelin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhiren, Li, Wenpan, Jiang, Yanhao, Tran, Tuyen Ba, Cordova, Leyla Estrella, Chung, Jinha, Kim, Minhyeok, Wondrak, Georg, Erdrich, Jennifer, Lu, Jianqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636136/ https://www.ncbi.nlm.nih.gov/pubmed/37945606 http://dx.doi.org/10.1038/s41467-023-43079-4

Ejemplares similares

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
por: Panfili, Eleonora, et al.
Publicado: (2023)

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
por: Jochems, Caroline, et al.
Publicado: (2016)

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
por: Komiya, Takefumi, et al.
Publicado: (2018)

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
por: Yue, Eddy W., et al.
Publicado: (2017)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine
por: Tahaghoghi-Hajghorbani, Sahar, et al.
Publicado: (2023)

Triple‐Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo‐Immunotherapy in Preclinical Cancer Models
por: Shi, Xiaowei, et al.
Publicado: (2023)

Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors
por: Naing, Aung, et al.
Publicado: (2022)

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
por: Luke, Jason J., et al.
Publicado: (2023)

An Electrokinetically-Driven Microchip for Rapid Entrapment and Detection of Nanovesicles
por: Shi, Leilei, et al.
Publicado: (2020)

Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy
por: Cheng, Qinzhen, et al.
Publicado: (2023)

ON THE COMPONENTS OF SPHINGOMYELIN
por: Levene, P. A.
Publicado: (1913)

Application of lipid nanovesicle drug delivery system in cancer immunotherapy
por: Ding, Yinan, et al.
Publicado: (2022)

Current Challenges for IDO2 as Target in Cancer Immunotherapy
por: Mondanelli, Giada, et al.
Publicado: (2021)

Raft-based sphingomyelin interactions revealed by new fluorescent sphingomyelin analogs
por: Kinoshita, Masanao, et al.
Publicado: (2017)

Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway
por: Lu, Jianqin, et al.
Publicado: (2018)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
por: Hellmann, Matthew D., et al.
Publicado: (2020)

Retraction of “Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway”
por: Lu, Jianqin, et al.
Publicado: (2021)

Ceramide/Sphingomyelin Rheostat Regulated by Sphingomyelin Synthases and Chronic Diseases in Murine Models
por: Taniguchi, Makoto, et al.
Publicado: (2020)

Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review
por: Alhamhoom, Yahya, et al.
Publicado: (2023)

Extracellular vesicles hybrid plasmid-loaded lipid nanovesicles for synergistic cancer immunotherapy
por: Tong, Qing, et al.
Publicado: (2023)

Engineering high‐affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy
por: Zhang, Luyao, et al.
Publicado: (2023)

Sphingomyelin generated by sphingomyelin synthase 1 is involved in attachment and infection with Japanese encephalitis virus
por: Taniguchi, Makoto, et al.
Publicado: (2016)

Sphingomyelins and ent-Sphingomyelins Form Homophilic Nano-Subdomains within Liquid Ordered Domains
por: Yano, Yo, et al.
Publicado: (2020)

Erythrocyte nanovesicles: Biogenesis, biological roles and therapeutic approach: Erythrocyte nanovesicles
por: Harisa, Gamaleldin I., et al.
Publicado: (2017)

Sphingomyelin is the master of its domain
por: Short, Ben
Publicado: (2014)

Nuclear sphingomyelin in neurodegenerative diseases
por: Albi, Elisabetta, et al.
Publicado: (2021)

Emphatic visualization of sphingomyelin-rich domains by inter-lipid FRET imaging using fluorescent sphingomyelins
por: Kinoshita, Masanao, et al.
Publicado: (2017)

Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin
por: Zheng, Kehong, et al.
Publicado: (2019)

Size-transformable antigen-presenting cell–mimicking nanovesicles potentiate effective cancer immunotherapy
por: Yang, Weijing, et al.
Publicado: (2020)

Phospholipid-Membrane-Based Nanovesicles Acting as Vaccines for Tumor Immunotherapy: Classification, Mechanisms and Applications
por: Chen, Wenjuan, et al.
Publicado: (2022)

Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and Immunotherapy
por: Peng, Jinrong, et al.
Publicado: (2018)

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
por: Gangadhar, Tara C, et al.
Publicado: (2015)

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
por: Naing, Aung, et al.
Publicado: (2022)

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
por: Powderly, John D, et al.
Publicado: (2022)

THE EFFECT OF SPHINGOMYELIN ON THE GROWTH OF TUBERCLE BACILLI
por: Dubos, René J.
Publicado: (1948)

Apoptosis and Sphingomyelin Hydrolysis: The Flip Side
por: Green, Douglas R.
Publicado: (2000)

The Multiple Roles of Sphingomyelin in Parkinson’s Disease
por: Signorelli, Paola, et al.
Publicado: (2021)

Deficiency of sphingomyelin synthase 1 but not sphingomyelin synthase 2 reduces bone formation due to impaired osteoblast differentiation
por: Matsumoto, Goichi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1rjl4k6o87c3p9fp7elkbjrnus